DOP2020000153A - Anticuerpos agonistas contra pd-1 y usos de estos - Google Patents

Anticuerpos agonistas contra pd-1 y usos de estos

Info

Publication number
DOP2020000153A
DOP2020000153A DO2020000153A DO2020000153A DOP2020000153A DO P2020000153 A DOP2020000153 A DO P2020000153A DO 2020000153 A DO2020000153 A DO 2020000153A DO 2020000153 A DO2020000153 A DO 2020000153A DO P2020000153 A DOP2020000153 A DO P2020000153A
Authority
DO
Dominican Republic
Prior art keywords
antibodies against
agonist antibodies
antibodies
tissues
human
Prior art date
Application number
DO2020000153A
Other languages
English (en)
Inventor
Marie Truhlar Stephanie
chai Qing
Peng Yiging
Paige Newburn Kristin
Verdino Petra
Pauliina Yachi Pia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2020000153A publication Critical patent/DOP2020000153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos agonistas anti-PD-1 humana y sus usos para tratar trastornos autoinmunitarios, tales como la artritis reumatoide, o para disminuir el rechazo de células y/o tejidos trasplantados.
DO2020000153A 2018-03-02 2020-08-05 Anticuerpos agonistas contra pd-1 y usos de estos DOP2020000153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637643P 2018-03-02 2018-03-02
PCT/US2019/019076 WO2019168745A1 (en) 2018-03-02 2019-02-22 Pd-1 agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DOP2020000153A true DOP2020000153A (es) 2020-09-15

Family

ID=65686121

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000153A DOP2020000153A (es) 2018-03-02 2020-08-05 Anticuerpos agonistas contra pd-1 y usos de estos

Country Status (26)

Country Link
US (1) US10493148B2 (es)
EP (1) EP3759139A1 (es)
JP (3) JP7071521B2 (es)
KR (2) KR20230079458A (es)
CN (1) CN111886253A (es)
AR (1) AR114127A1 (es)
AU (2) AU2019228474B2 (es)
BR (1) BR112020015983A2 (es)
CA (1) CA3092064C (es)
CL (1) CL2020002180A1 (es)
CO (1) CO2020010188A2 (es)
CR (1) CR20200375A (es)
DO (1) DOP2020000153A (es)
EA (1) EA202091809A1 (es)
EC (1) ECSP20053544A (es)
IL (1) IL276340A (es)
JO (1) JOP20200210A1 (es)
MA (1) MA52414A (es)
MX (1) MX2020009124A (es)
PE (1) PE20210045A1 (es)
PH (1) PH12020551463A1 (es)
SA (1) SA520420082B1 (es)
SG (1) SG11202008437WA (es)
TW (1) TWI708787B (es)
WO (1) WO2019168745A1 (es)
ZA (1) ZA202004601B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066561A2 (en) * 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR20200010354A (ko) 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
WO2018226580A2 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US20210061912A1 (en) * 2018-03-20 2021-03-04 WuXi Biologics Ireland Limited Novel anti-pd-1 antibodies
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
BR112022021392A2 (pt) * 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
KR20230015348A (ko) * 2020-05-25 2023-01-31 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
EP4157876A1 (en) 2020-05-26 2023-04-05 Boehringer Ingelheim International GmbH Anti-pd-1 antibodies
WO2022239820A1 (ja) 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
WO2023089377A2 (en) 2021-11-19 2023-05-25 Mirobio Limited Engineered pd-1 antibodies and uses thereof
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
WO2024010861A2 (en) * 2022-07-06 2024-01-11 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2024040206A2 (en) * 2022-08-19 2024-02-22 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
WO2024050421A2 (en) * 2022-08-30 2024-03-07 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting programmed cell death protein 1 (pd-1)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2009026472A1 (en) 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
CA2736816C (en) * 2008-09-12 2018-05-22 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
JP5920929B2 (ja) 2010-03-11 2016-05-18 ユセベ ファルマ ソシエテ アノニム Ｐｄ−１抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2742953B1 (en) * 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
WO2016020856A2 (en) * 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
CN108337890B (zh) 2015-06-23 2021-10-15 纪念斯隆-凯特琳癌症中心 新型pd-1免疫调节剂
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
HRP20221041T1 (hr) 2015-10-02 2022-11-11 Symphogen A/S Anti-pd-1 antitijela i sastavi
PE20181092A1 (es) 2015-10-02 2018-07-09 Hoffmann La Roche Anticuerpos anti-pd1 y metodos de uso
WO2017096026A1 (en) 2015-12-02 2017-06-08 Stcube, Inc. Antibodies specific to glycosylated pd-1 and methods of use thereof
WO2018226580A2 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Antibodies that specifically bind pd-1 and methods of use

Also Published As

Publication number Publication date
EA202091809A1 (ru) 2020-11-23
EP3759139A1 (en) 2021-01-06
SA520420082B1 (ar) 2022-11-11
WO2019168745A1 (en) 2019-09-06
JP2022088411A (ja) 2022-06-14
MX2020009124A (es) 2020-09-28
CR20200375A (es) 2020-09-25
TWI708787B (zh) 2020-11-01
CL2020002180A1 (es) 2021-01-04
AU2019228474A1 (en) 2020-08-20
CO2020010188A2 (es) 2020-08-31
JP2021516235A (ja) 2021-07-01
AU2023204569A1 (en) 2023-10-26
PH12020551463A1 (en) 2021-09-01
JOP20200210A1 (ar) 2020-08-30
IL276340A (en) 2020-09-30
KR20230079458A (ko) 2023-06-07
PE20210045A1 (es) 2021-01-08
BR112020015983A2 (pt) 2020-12-15
US10493148B2 (en) 2019-12-03
JP7259107B2 (ja) 2023-04-17
ZA202004601B (en) 2022-03-30
ECSP20053544A (es) 2020-10-30
SG11202008437WA (en) 2020-09-29
CA3092064A1 (en) 2019-09-06
KR102536014B1 (ko) 2023-05-24
MA52414A (fr) 2021-01-06
CA3092064C (en) 2024-01-02
US20190270818A1 (en) 2019-09-05
AU2019228474B2 (en) 2023-04-13
KR20200115614A (ko) 2020-10-07
JP2023093549A (ja) 2023-07-04
JP7071521B2 (ja) 2022-05-19
AR114127A1 (es) 2020-07-22
CN111886253A (zh) 2020-11-03
TW201942133A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
CO2020010188A2 (es) Anticuerpos agonistas contra pd-1 y usos de estos
ECSP17085333A (es) Anticuerpos anti-cd40 y sus usos.
CL2021001573A1 (es) Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos.
PE20211594A1 (es) Anticuerpos biespecificos contra el a-beta humano y el receptor de transferrina humano y metodos de uso
BR112017005390A2 (pt) células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
CL2021001661A1 (es) Compuestos de heterociclil piridazina como fungicidas
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
CL2020002613A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CU20130071A7 (es) VARIANTES DE Fc SILENCIOSAS DE LOS ANTICUERPOS ANTI- CD40
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CL2017002106A1 (es) Anticuerpos contra tau y sus usos
ECSP19059553A (es) Anticuerpos anti-tgf-beta y su uso
ECSP12011980A (es) Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana.
EA201892005A1 (ru) Композиции и способы для лечения ревматоидного артрита
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
CL2021000606A1 (es) Anticuerpos agonistas contra cd200r y sus usos
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
ECSP22041169A (es) Anticuerpos trem2 y usos de estos
MX2016016664A (es) Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
AR120820A1 (es) Composiciones y métodos de tratamiento del cáncer con receptores de antígenos quiméricos dirigidos al glipicano 3
UY39111A (es) Compuestos para su uso en afecciones autoinmunitarias
IL269833A (en) New uses of stem cells derived from mammalian muscle
EA201990353A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ СПОСОБНОСТЬЮ НЕЙТРАЛИЗОВАТЬ ГЛАВНЫЕ ЭКЗОТОКСИНЫ TcdA И TcdB Clostridium difficile